Skip to main content

ASH Highlights

Meeting Highlights

ASH Highlights

Depth of Response of Isatuximab + Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Interim Analysis

Meeting Highlights

ASH Highlights

Teclistamab, a BCMA x CD3 Bispecific Antibody, in Patients with RRMM: Phase 1 Study Updates

Meeting Highlights

ASH Highlights

Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, for RRMM

Meeting Highlights

ASH Highlights

Novel Therapeutic Strategies with P-BCMA-101 CAR T-Cells in Patients with RRMM: Phase 1/2 Study Results

Meeting Highlights

ASH Highlights

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with RRMM

Meeting Highlights

ASH Highlights

ANCHOR: Melflufen + Dexamethasone and Daratumumab or Bortezomib in RRMM Patients Refractory to an IMiD and/or Proteasome Inhibitor

Meeting Highlights

ASH Highlights

Systematic Review and Network Meta-Analysis of the Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-Refractory Multiple Myeloma

Meeting Highlights

ASH Highlights

APOLLO: Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM

Meeting Highlights

ASH Highlights

BFCR4350A, a FcRH5 x CD3 T-Cell–Engaging Bispecific Antibody, in Patients with RRMM: Preliminary Clinical Activity and Safety

Meeting Highlights

ASH Highlights

Cobimetinib as Monotherapy and in Combination with Venetoclax with or without Atezolizumab in Patients with RRMM

1
2
3
4
5
6

Page 3 of 7
Results 21 - 30 of 70